Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,188 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,266 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | recruiting | Phase 1 | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07039201 | A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) | recruiting | N/A | 12 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07345247 | RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study(RASEREM) | recruiting | — | 150 | Ankara UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07359586 | Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia | recruiting | — | 1,200 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05155189 | A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07328607 | Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy | recruiting | N/A | 90 | Minia UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07356531 | Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer | recruiting | N/A | 216 | JIANGSU SHENMING Medical Technology CO., LtdINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05366881 | cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease(CAMPERR) | recruiting | — | 7,000 | Adela, IncINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06689670 | Needle-based Percutaneous Ablation of Liver Tumors. | recruiting | N/A | 31 | inTumo Therapeutics, Inc.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06227728 | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.(PTC-IMPACT) | recruiting | — | 50 | Gene SolutionsINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07324824 | Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma | recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study(SCORE) | recruiting | — | 9,600 | Natera, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05668884 | GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06405321 | Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma | recruiting | — | 2,000 | Guangxi Medical UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07235007 | Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma(BRAVE) | recruiting | N/A | 120 | Aichi Medical UniversityOTHER | 2 | Jan 13, 2026 | clinicaltrials |
| NCT07337421 | Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337460 | Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors | recruiting | Phase 2 | 30 | Northern Jiangsu People's HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07337850 | Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers(FAPi-2) | recruiting | — | 60 | Tata Memorial CentreOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT03894917 | Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma | recruiting | — | 84 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07325565 | Impact of Emotional Disorders on Response to Immune Checkpoint Inhibitor Therapy in Liver Cancer | recruiting | — | 651 | Tongji HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07327034 | ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression | recruiting | Phase 2 | 141 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07324304 | NWRD06 DNA Plasmid for HCC After Curative Resection. | recruiting | Phase 2 | 30 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06526104 | Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | recruiting | Phase 2 | 32 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07317414 | β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 158 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06590246 | A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 121 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT07315633 | An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer | recruiting | — | 80 | University Hospital, GhentOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06715839 | Target-specific immunoPET Imaging of Digestive System Carcinoma | recruiting | N/A | 400 | RenJi HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310173 | Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 75 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06490757 | A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular Adenomas(JAKIH) | recruiting | Phase 2 | 25 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06828380 | A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion(IOPT) | recruiting | Phase 2 | 128 | National Cancer Center, KoreaOTHER_GOV | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07303712 | Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 | recruiting | — | 12 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07303725 | Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology | recruiting | — | 30 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05727787 | vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC(vGRID SBRT) | recruiting | N/A | 18 | University of Kansas Medical CenterOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04587739 | Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.(KARCHER-1) | recruiting | Phase 1 | 30 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07300449 | A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents | recruiting | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06523608 | Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease(DETECT) | recruiting | — | 600 | University Hospital MuensterOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07291141 | A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis(DETECT-HCC) | recruiting | — | 600 | Mattias EkstedtOTHER_GOV | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07295262 | NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC | recruiting | Early Phase 1 | 30 | West China HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07295340 | Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection | recruiting | — | 20 | West China HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05317819 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 300 | Polaris GroupINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT06478693 | A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | recruiting | Phase 1 | 70 | Myeloid TherapeuticsINDUSTRY | 3 | Dec 18, 2025 | clinicaltrials |
| NCT07275073 | JMT106 Injection in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 200 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07282184 | Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention | recruiting | Phase 1 / Phase 2 | 144 | Tongji HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291063 | Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA | recruiting | — | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2026source: clinicaltrials